Pediatric Long-Term Follow-up and Rollover Study

Key Inclusion Criteria:

All Subjects:

• Written informed consent, according to local guidelines, signed by the subjectsand/or by the parents or legal guardian prior to any study related screeningprocedures are performed.

• Participation in a Novartis sponsored study such as CTMT212X2101, CDRB436G2201,CDRB436A2102, regardless of current age.

• Parent study (or cohort of parent study) is planned to be closed.

• Subject has demonstrated compliance, as assessed by the investigator, within theparent study protocol requirement(s).

• Willingness and ability to comply with scheduled visits, treatment plans and anyother study procedures.

For Subjects Entering the Treatment Period:

• Subject is currently receiving treatment with dabrafenib/trametinib monotherapy orcombination within a Novartis Sponsored Drug Development study. Note that subjectswho were on the chemotherapy arm of the CDRB436G2201 study are eligible fortreatment period of this study only after crossing over into the experimentaltreatment arm of the CDRB436G2201 study

• In the opinion of the investigator is likely to benefit from continued treatment.

Key Exclusion Criteria:

All Subjects:

• Subject has participated in a combination trial where dabrafenib and/or trametinib was dispensed in combination with another study medication.

For Subjects Entering the Treatment Period:

• Subject has permanently discontinued from study treatment in the parent protocol dueto any reason.

• Treatment with dabrafenib and/or trametinib for the subject's indication is approvedfor marketing and the appropriate dosage form is commercially available andreimbursed in the local country

• Subject currently has unresolved drug related severe toxicities for which dabrafeniband/or trametinib dosing has been interrupted in the parent study. If the subjectshould meet criteria to resume treatment on the parent protocol then they may beeligible for treatment in this study.

Other protocol-defined inclusion/exclusion may apply.